Roche Diagnostics Gmbh

Hoffmann-la Roche Inc.

Sanofi Biotechnology Sas

Boehringer Mannheim Gmbh

Roche Palo Alto LLC

Sanofi Biotechnology

Mab Discovery Gmbh

F. Hoffmann-la Roche Ag

Michael Brandt

Stephan Fischer

Anne Stern

Konrad Honold

Reinhard Franze

Hans Koll

Johannes Auer

Ulrich Pessara

Winfried Albert

Herbert Jungfer

Josef Endl

Stefan Seeber

Georg Fertig

Ralf Schumacher

Hans-Willi Krell

Edgar Voss

Thomas Von Hirschheydt

Rosemarie Kientsch-Engel

Wiltrud Richter

Linda Veronique Kazandjian

Werner Scherbaum

Thomas Eiermann

Erhard Kopetzki

Klaus Kaluza

Jens Fischer

Monika Baehner

Suryanarayana Sankuratri

Stefan Jenewein

Apollon Papdimitriou

Surya Sankuratri

Eileen Samy

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

Monoclonal anti-IL-1RAcP antibodies

Monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody.

HER-2 binding antibodies

The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Humanized anti-IL-1R3 antibodies

The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

Monoclonal antibody that specifically binds IL-1RAcP, or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616 The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

Monoclonal anti-IL-1RAcp antibodies

The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. The invention also relates to the use of an antibody according to the invention in the treatment of a HER-2 mediated disease. The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention, and the use of said composition in the treatment of a HER-2 mediated disease.

Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616. The monoclonal antibody is characterized in that it inhibits IL-1RAcP induced NFkB activity, useful in treatment of IL-1RAcP related diseases.

The invention provides anti-IL-18R1 antibodies and methods of using the same.

Antibodies against IL-18R1 and uses thereof

The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.

Conjugate of an antibody against CCR5 and an antifusogenic peptide

The present invention provides a conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 molecules in the composition. Also provided is a composition in which the monoPEGylated conjugates comprise conjugates in which the PEG groups are attached to groups randomly selected from the lysine side chains of NK4 molecules and the N-terminal amino groups of NK4 molecules. A method for the treatment of cancer by administering 1 to 30 mg monoPEGylated NK4 per kg per day is further provided.

PEG conjugates of NK4

Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.

Antibodies against CCR5 and uses thereof

A process for selecting human cells for the production of human proteins by endogenous gene activation allows human proteins to be produced in economically feasible quantities and in a form suitable for producing a pharmaceutical composition. Also disclosed is a process for producing human proteins in a cell line identified in this matter.

Identification of human cell lines for the production of human proteins by endogenous gene activation

The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.

Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof

The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.

Preparation of erythropoietin by endogenous gene activation

This invention is directed to compounds of formula (I), which are valuable therapeutics for the treatment of cancer and cancer related diseases.

Growing community of inventors

Iffeldorf, Germany

Michael Brandt